UTHR UNITED THERAPEUTICS Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1082554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.9%
TTM net income YoY-3.2%
TTM EPS YoY0.4%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR11.0%
Margins
Gross margin86.3%
Operating margin41.4%
Net margin38.6%
FCF margin27.2%
EBITDA margin44.5%
Returns
ROE19.1%
ROA17.1%
ROIC (approx.)20.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets10.8%
Debt / equity0.00x
Current ratio4.61x
Interest coverage111.02x
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue17.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $832.50M | $783.30M | $781.50M | $790.20M | $799.50M | $798.60M | $794.40M | $735.90M |
| Cost of revenue | $99.10M | $99.50M | $133.40M | $103.40M | $100.90M | $87.60M | $92.50M | $75.90M |
| Gross profit | $733.40M | $683.80M | $648.10M | $686.80M | $698.60M | $711.00M | $701.90M | $660.00M |
| R&D expense | $279.20M | $146.30M | $138.20M | $139.50M | $127.50M | $134.00M | $149.00M | $133.80M |
| SG&A expense | $146.40M | $206.70M | $184.10M | $190.60M | $182.60M | $212.50M | $170.10M | $168.50M |
| Operating income | $307.80M | $330.80M | $325.80M | $356.70M | $388.50M | $364.50M | $382.80M | $357.70M |
| Interest expense | $2.90M | $2.90M | $3.00M | $3.10M | $3.00M | $7.30M | $6.10M | $7.90M |
| Pretax income | $372.80M | $372.70M | $318.30M | $444.00M | $438.00M | $408.40M | $423.50M | $396.50M |
| Income tax | $114.20M | $39.70M | $43.40M | $79.70M | $99.30M | $98.90M | $101.30M | $95.20M |
| Net income | $258.60M | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M | $322.20M | $301.30M |
| EBITDA | $334.20M | $355.00M | $348.40M | $379.50M | $410.40M | $385.60M | $402.60M | $377.40M |
| EPS (basic) | 6.06 | 7.82 | 6.32 | — | 7.73 | 6.86 | 7.18 | — |
| EPS (diluted) | 5.71 | 7.27 | 5.82 | — | 7.16 | 6.41 | 6.63 | — |
| Weighted avg. shares (diluted) | 45.30M | 45.80M | 47.20M | — | 47.30M | 48.30M | 48.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.19B | $1.80B | $1.28B | $1.56B | $1.34B | $1.59B | $1.90B | $1.70B |
| Short-term investments | $879.00M | $859.10M | $874.00M | $1.36B | $1.43B | $1.46B | $1.42B | $1.57B |
| Receivables | $348.60M | $310.30M | $312.00M | $350.20M | $297.70M | $379.30M | $322.00M | $279.30M |
| Inventory | $201.90M | $193.80M | $178.30M | $183.10M | $176.50M | $169.20M | $165.40M | $157.90M |
| Current assets | $2.88B | $3.48B | $2.87B | $3.70B | $3.49B | $3.83B | $3.94B | $3.87B |
| PP&E, net | $2.04B | $1.93B | $1.84B | $1.73B | $1.56B | $1.36B | $1.30B | $1.22B |
| Goodwill | — | — | — | $32.30M | — | — | — | $32.30M |
| Total assets | $7.03B | $7.22B | $6.71B | $7.88B | $7.35B | $7.91B | $7.74B | $7.36B |
| Current liabilities | $624.30M | $607.80M | $599.10M | $560.60M | $546.30M | $527.10M | $721.50M | $738.10M |
| Total liabilities | $758.10M | $819.80M | $813.10M | $783.80M | $760.90M | $734.40M | $936.70M | $920.00M |
| Shareholders' equity | $6.28B | $6.40B | $5.90B | $7.10B | $6.59B | $7.17B | $6.81B | $6.44B |
| Shares outstanding | 42.38M | 42.68M | 42.16M | 43.64M | 42.90M | 45.22M | 45.07M | 44.83M |
| Cash flow statement | ||||||||
| Operating cash flow | $306.50M | $313.60M | $463.30M | $346.20M | $562.10M | $191.70M | $461.20M | $341.20M |
| Capital expenditure | $180.70M | $108.00M | $100.80M | $172.90M | $210.50M | $62.20M | $74.90M | $86.70M |
| Free cash flow | $125.80M | $205.60M | $362.50M | $173.30M | $351.60M | $129.50M | $386.30M | $254.50M |
| Investing cash flow | -$510.60M | $87.50M | $743.70M | -$227.60M | $140.90M | -$299.90M | -$164.70M | -$123.20M |
| Financing cash flow | -$410.20M | $122.40M | -$1.48B | $98.40M | -$956.00M | -$198.60M | -$93.80M | -$74.70M |
| Depreciation & amortization | $26.40M | $24.20M | $22.60M | $22.80M | $21.90M | $21.10M | $19.80M | $19.70M |
| Stock-based compensation | $41.00M | $43.40M | $33.90M | $39.00M | $39.10M | $37.80M | $31.80M | $27.00M |
| Share buybacks | $500.00M | $0 | $1.50B | $0 | $1.00B | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.